Paradiem, LLC Harmony Biosciences Holdings, Inc. Transaction History

Paradiem, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$29.93 - $35.06 $392,112 - $459,321	-13,101 Reduced 12.24%	93,930 $3.15 Million
Q4 2023 Feb 05, 2024	BUY	$19.2 - $33.78 $573,062 - $1.01 Million	29,847 Added 38.67%	107,031 $3.46 Million
Q3 2023 Oct 30, 2023	BUY	$31.89 - $39.03 $562,858 - $688,879	17,650 Added 29.65%	77,184 $2.53 Million
Q2 2023 Jul 18, 2023	SELL	$30.5 - $37.4 $227,560 - $279,041	-7,461 Reduced 11.14%	59,534 $2.1 Million
Q1 2023 Apr 10, 2023	BUY	$30.8 - $53.92 $352,906 - $617,815	11,458 Added 20.63%	66,995 $2.19 Million
Q4 2022 Jan 24, 2023	BUY	$45.4 - $60.91 $154,587 - $207,398	3,405 Added 6.53%	55,537 $0
Q3 2022 Oct 18, 2022	BUY	$42.06 - $55.45 $2.19 Million - $2.89 Million	52,132 New	52,132 $2.31 Million

242

45.1M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.05B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Paradiem, LLC, based on Form 13F filings with the SEC.

Stay updated on Paradiem, LLC with notifications on news.